Oncology diagnostics
14 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Marcus Healey
Scoop.it!

Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma - Delgado-Goñi - 2014 - NMR in Biomedicine - Wiley Online Library

Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma - Delgado-Goñi - 2014 - NMR in Biomedicine - Wiley Online Library | Oncology diagnostics | Scoop.it
Precision Medicine @Work: Molecular imaging and machine learning http://t.co/8ipFRnzZ1c
Marcus Healey's insight:

In patients with glioblastoma multiforme (GBM), a type of brain tumor, some individuals respond to temozolomide better than others. The  type of imaging described in this article will better help identify that subpopulation of patients that might be able to better respond to TMZ, therefore calming payer anxiety, and increasing response in treated patients.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Rutgers receives $10 million anonymous donation for advanced cancer treatment - RU Daily Targum

Rutgers receives $10 million anonymous donation for advanced cancer treatment - RU Daily Targum | Oncology diagnostics | Scoop.it

Rutgers receives $10 million anonymous donation for advanced cancer treatment
RU Daily Targum
By continuing and expanding this personalized care through the Precision Medicine Initiative, patients will receive the best possible care, he said.

Marcus Healey's insight:

Rutgers University is my graduate school alma mater. They have been investing for years in infrastructure and talented professors and students. RU, a hidden secret in higher education! Good value for money in NJ.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Worldwide Molecular Diagnostics Market Worth $8020.1 Million by 2020: Grand ... - WhaTech

Worldwide Molecular Diagnostics Market Worth $8020.1 Million by 2020: Grand ...
WhaTech
Oncology applications dominated the overall market in 2013, accounting for over 30% of total revenue.
Marcus Healey's insight:

That is an incredible amount of money....but the tip of the iceberg as many Dx move to POCT/NPT.

more...
No comment yet.
Rescooped by Marcus Healey from Oncology diagnostics
Scoop.it!

DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis - HealthCanal.com

DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis - HealthCanal.com | Oncology diagnostics | Scoop.it
DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis HealthCanal.com The fragments, known as cell-free circulating tumor DNA (ctDNA), were detected in the blood of more than 75 percent of patients with advanced cancers and in at...

Via Gilbert C FAURE, Marcus Healey
Marcus Healey's insight:

Important free full text paper for those of us following the development of new, non-invasive POC diagnostics that can greatly influence cancer care through better patient management and the tracking of resistance (http://www.ncbi.nlm.nih.gov/pubmed/24553385).

more...
No comment yet.
Rescooped by Marcus Healey from health technology assessment emerging countries
Scoop.it!

New EU plan to fast-track next-generation drugs launches - PharmaTimes

New EU plan to fast-track next-generation drugs launches - PharmaTimes | Oncology diagnostics | Scoop.it
New EU plan to fast-track next-generation drugs launches
PharmaTimes
The project will aim to advance understanding of the condition and address the lack of tools and technologies to detect people's risk of developing it.
Marcus Healey's insight:

Innovative Medicines Initiative 2. Focus high unmet/societal need: diabetes and retinal diseases. Unsurprising given run up to projected 400 mn people living with diabetes worldwide and impt of trmnts for retinal diseases.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Why Are Companion Diagnostics So Important? - Motley Fool

Why Are Companion Diagnostics So Important?
Motley Fool
Over the last year, biotech investors have been consumed by excitement surrounding a new class of cancer drugs that uses the body's own defenses to battle tumors.
Marcus Healey's insight:

This is why CDx are so important: identification of patient responder population. That way the right patient gets the right drug, which calms payer anxiety as well.

 

http://www.fool.com/investing/general/2014/06/30/why-are-companion-diagnostics-so-important.aspx

 

more...
No comment yet.
Rescooped by Marcus Healey from Lung Cancer Dispatch
Scoop.it!

Blood Test Accurate in Later Stage Lung Cancer Diagnosis

Blood Test Accurate in Later Stage Lung Cancer Diagnosis | Oncology diagnostics | Scoop.it

"Simple blood tests for cancer diagnosis and post-treatment assessment are getting closer all the time. New research has shown that a new assay for measuring circulating tumor DNA (ctDNA) could detect essentially all stage II-IV non-small-cell lung cancers (NSCLC), and is even about 50% sensitive in finding stage I NSCLC as well."


" 'Analysis of ctDNA has the potential to revolutionize detection and monitoring of tumors,' wrote investigators led by senior study author Maximilian Diehn, MD, PhD, of Stanford University School of Medicine, in Nature Medicine. 'Noninvasive access to cancer-derived DNA is particularly attractive for solid tumors, which cannot be repeatedly sampled without invasive procedures.' "


Via Cancer Commons
more...
Cancer Commons's curator insight, April 24, 2014 2:57 PM

Cancer Network  |  Apr 24, 2014

Rescooped by Marcus Healey from from Flow Cytometry to Cytomics
Scoop.it!

DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis - HealthCanal.com

DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis - HealthCanal.com | Oncology diagnostics | Scoop.it
DNA Shed By Tumors Show Promise for Non-Invasive Screening and Prognosis HealthCanal.com The fragments, known as cell-free circulating tumor DNA (ctDNA), were detected in the blood of more than 75 percent of patients with advanced cancers and in at...

Via Gilbert C FAURE
more...
Marcus Healey's curator insight, July 9, 2014 4:52 PM

Important free full text paper for those of us following the development of new, non-invasive POC diagnostics that can greatly influence cancer care through better patient management and the tracking of resistance (http://www.ncbi.nlm.nih.gov/pubmed/24553385).

Scooped by Marcus Healey
Scoop.it!

NIH Director: China Leads US in Genomic Research - Health Data Management

NIH Director: China Leads US in Genomic Research - Health Data Management | Oncology diagnostics | Scoop.it
NIH Director: China Leads US in Genomic Research Health Data Management Personalized and precision medicine and how we do it is really our moment in time,” said Dan Theodorescu, M.D., director of the University of Colorado Comprehensive Cancer...
Marcus Healey's insight:

China has used the US Genome project outputs and leveraged them greatly to their advantage. Huge inroads have also been made by China in terms of offering pathology lab services.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Ventana collaborates with Merck KGaA to develop companion diagnostic test for ... - pharmabiz.com

Ventana collaborates with Merck KGaA to develop companion diagnostic test for ...
Marcus Healey's insight:

Many targets...many partners.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Companion Diagnostics Are Driving Support in the Evolving Regulatory Landscape

Companion Diagnostics Are Driving Support in the Evolving Regulatory Landscape | Oncology diagnostics | Scoop.it
Owing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.
Marcus Healey's insight:

CDx will calm payer anxiety but many payers are not sure who will pay for the Dx: HTA in EU, CMO/insurer in US, hospital, via DRG, Dx manufacturer or Tx manufacturer. Either way, payments are cost- and not value-based.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle

Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle | Oncology diagnostics | Scoop.it
Marcus Healey's insight:

This is an important paper. It provides proof-of-principle that massively parallel sequencing of plasma-derived cell-free tumor DNA (ctDNA) can be a surrogate for tissue-based testing and this technique can be employed to track mutations and resistance in cancer patients. This technique helps to overcome the limitations imposed by intra-tumor genetic heterogeneity. From a MA P&R perspective, ctDNA biopsies can be employed to be sure that the right patient is getting the right drug (e.g., Vectibix or Erbitux in mCRC) and to track the inevitable advent of resistance, which might require a switch to another biologic. Patient management will improve; payer anxiety may be reduced with the introduction of these types of diagnostics, particularly if they are used in a timely manner (http://annonc.oxfordjournals.org/content/early/2014/07/08/annonc.mdu239.short?rss=1).

more...
No comment yet.
Rescooped by Marcus Healey from health technology assessment emerging countries
Scoop.it!

European Pharma Policy Reaches "New Level of Timidity" - PharmExec.com (blog)

European Pharma Policy Reaches "New Level of Timidity" PharmExec.com (blog) But with the emergence of rival health technology assessment methods across Europe, “diverging requirements between Member States can lead to shortcomings in the efficient...
Marcus Healey's insight:

EU, once again, snatching defeat from jaws of victory by organizing another meeting for industry insiders and stakeholders about ways to boost the drug industry. In the eyes of veteran EU pharma policy observers this was another instance where EU officials sunk to new levels of pusillanimity and timidity about ways to boost an industry with access challenges occur along the value chain from discovery of a medicine to the use by the patient.

more...
No comment yet.
Rescooped by Marcus Healey from OMICs for R&D
Scoop.it!

Crowdsourcing a Cure for Breast Cancer - $100 million and Game on at GE - Forbes

Crowdsourcing a Cure for Breast Cancer - $100 million and Game on at GE - Forbes | Oncology diagnostics | Scoop.it
GE has followed up its highly successful Ecomagination campaign with one called healthymagination and its first target is breast cancer. O’Reilly Media wrote about it here. I find it hard to commend GE highly enough. They’ve teamed up with 4 leading VC firms (Kleiner Perkins Caufield & Beyers, Mohr Davidow Ventures, Venrock, and MPM Capital.) to help speed any new ideas in early detection and cure through to market. But for any developer, data geek or designer with a new perspective you’ve got 28 days left.

So far there are 37 ideas up on the site and by and large they look as though they come from the existing diagnostics and treatment community. Hopefully that will change and more people from the developer community will pitch in.

A more open ended call might help people outside the core area of oncology and diagnostics to gear up and get involved. The crowd might not have the specialist reach of the oncology profession but there’s something in the cancer experience that really begs for new perspectives.

So the use of a crowsourced model is the most inspiring part of the GE initiative, and any criticism is just picking over the detail.

And there’s more.

GE have set up a Facebook page where women can talk about the detection process. That part of the challenge is there to help designers get a better insight into what women go through before detection and onwards. It’s a crowdsourced user-experience document and the idea to help designers to optimise the patient journey.

As part of a more social approach to cancer GE is also aggregating online patient conversation around cancer.

But at the heart of the initiative is detection and cure.

Here’s how GE describes the core research challenge:

GE’s first healthymagination Challenge is an open call to action for oncology researchers, businesses, students, and healthcare innovators to submit ideas that will accelerate innovation in breast cancer. Through the Challenge, GE and its venture capital partners will award up to $100 million to fund these breakthrough ideas that advance early detection, more accurate diagnoses and targeted treatment of breast cancer.

For people who’ve been through the cancer mill this ought to be an inspirational moment. But perhaps that depends on your view of alternatives to the current oncology regime. There’s an important debate waiting to be had about how our current peer review and esteem systems exclude novel approaches to cure.

There’s also an opportunity that might go missing – to fully involve patients in the search and discovery process.

Patients are experts at what it is like to experience cancer and at whether or not lifestyle choices may have contributed to onset. I still can’t help feeling that this data is overlooked. And that a truly elastic approach to innovation would incorporate patient experience not just in redesigning mammography but also in understanding recovery, longevity and cure.

Crowdsourcing has the power to bring totally new perspectives to the battle. With luck it will create a breakthrough and if it does it will change how we set about addressing major societal problems. My only reservation is that November 20th deadline. I hope GE think again about that.


Via Chatu Jayadewa
more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Dr. Diamond on a Comparison of Urine Testing to Tissue Biopsy

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses an analysis that looked at urine and plasma cell-free DNA BRAFV600E testin...
more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, Mark Sausen, Rebecca J. Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence C. Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung Le, Robert L. Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung-Mo Hong, Yuchen Jiao, Hartmut H. Juhl, Jenny J. Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore-Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba-Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian-Li Wang, Jon D. Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Diaz Jr

 

Sci Transl Med 19 February 2014: Vol. 6, Issue 224, p. 224ra24

 

The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction–based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in >75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.

more...
No comment yet.
Scooped by Marcus Healey
Scoop.it!

Biocept (NASDAQCM: BIOC) - RedChip Global Online CEO Conference

Presentation and Investor Q&A with Mike Nall, CEO of Biocept (NASDAQCM: BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cel...
more...
No comment yet.